Delving into the Latest Updates on Cefotetan Disodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid, Cefotetan disodium (USP), Cefotetan sodium (JAN)

+ [6]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Infectious DiseasesBacterial InfectionsComplicated intra-abdominal infection+ [7]

Inactive Indication

Acute BronchitisBronchiectasisBronchitis, Chronic+ [3]

Originator Organization

VJGJ, Inc.

Active Organization

Hubei Jumpcan Pharmaceutical Co., Ltd.Shandong Teruilin Medicine Technology Development Co., Ltd.PAI Holdings LLC

+ [1]

Inactive Organization

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

B. Braun Medical, Inc.

Drug Highest PhaseApproved

First Approval Date

US (27 Dec 1985),

Infectious Diseases

Regulation-

Login to view timeline

Structure

Molecular FormulaC17H17N7NaO8S4

InChIKeyBTOFDTWBLNLGSY-DWUNWFSHSA-N

CAS Registry74356-00-6

529 patients performed elective LCC at Chonbuk National University Hospital between April 2014 and August 2015. Total 509 patients were enrolled by inclusion criteria.
They were randomized studied by comparing with antibiotic group (n=249, AG, cefotetan 1g, 1 dose/prophylactic) and non-antibiotic group (n=260, NAG) by table of random numbers. The clinical variables were pre and post-operatively blood tests enclude WBC, ESR, CRP, body temperatures, symptoms and imaging of chest x-ray to evaluate the infections.

Start Date01 Apr 2014

Sponsor / Collaborator

Jeonbuk National University Hospital

CTR20131216 / CompletedPhase 2

评价注射用头孢替坦二钠治疗呼吸和泌尿系统中、重度急性细菌性感染性疾病有效性和安全性的Ⅱ期临床试验

[Translation] Phase II clinical trial to evaluate the efficacy and safety of cefotetan disodium injection in the treatment of moderate to severe acute bacterial infections in the respiratory and urinary systems

以注射用头孢美唑钠为对照，评价注射用头孢替坦二钠治疗呼吸系统、泌尿系统急性细菌感染性疾病的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of cefotetan disodium injection in the treatment of acute bacterial infections of the respiratory and urinary systems, using cefmetazole sodium injection as a control.

Start Date10 Oct 2012

Sponsor / Collaborator

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with Cefotetan Disodium

Login to view more data

100 Translational Medicine associated with Cefotetan Disodium

Login to view more data

100 Patents (Medical) associated with Cefotetan Disodium

Login to view more data

807

Literatures (Medical) associated with Cefotetan Disodium

01 Oct 2024·Indian Journal of Otolaryngology and Head & Neck Surgery

Audiological Profile of a Rare Case with 1 kHz Notch Audiogram

Article

Author: Bhat, Mayur ; Gupta, Swati ; Jyotsna, CS ; Rao, Chandana N ; Somaya, K Zana ; Jyotsna, C S

A notch is defined as the frequency point at which hearing loss is greater than 15 dB when compared to one octave above and below. C3 dip or 1 kHz notch is rarely seen and not much information is known about the clinical profile of such condition. The aim of this case report is to highlight the audiological profile of a case with 1kHz notch and discuss the possible causes for the same. Case A (16 yrs) was referred with a complaint of hearing loss and speech understanding difficulty specially at school. The teen had taken multiple medications for several health related issues like malaria, appendicitis and the understanding difficulty was evident during this period. Detailed audiological evaluation revealed a significant C3 dip in the right ear and normal hearing sensitivity in the left ear. Evidences from literature suggests strong correlation between drugs like Cefotetan, cefotaime, piperacillin, ampicillin (appendicitis treatment) and chloroquine (malaria) and hearing loss. Hence, we concluded that the possible cause of 1khz is ototoxic medication.

30 Sep 2024·Annals of Laboratory Medicine

Evaluation of the Disk Diffusion Test for Bacteroides fragilis Group Clinical Isolates

Article

Author: Lee, Hyukmin ; Lee, Kyungwon ; Bae, Mi-Hyun ; Kim, Myungsook ; Lee, Yangsoon

BackgroundBacteroides fragilis group (BFG) isolates are the most frequently isolated gram-negative anaerobic bacteria and exhibit higher levels of antimicrobial resistance than other anaerobic bacteria. Reliable susceptibility testing is needed because of reports of resistance to the most active antibiotics. Recently, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) introduced disk zone diameter breakpoints. We evaluated the disk diffusion test (DDT) for susceptibility testing of BFG isolates compared with the agar dilution method.MethodsIn total, 150 BFG isolates were collected from three institutes in Korea. The agar dilution method was conducted according to the CLSI guidelines. DDT was performed following the EUCAST guideline. Fastidious anaerobe agar supplemented with 5% defibrinated horse blood was used as the culture medium. Nine antimicrobials were evaluated: penicillin, cefoxitin, cefotetan, imipenem, meropenem, piperacillin-tazobactam, clindamycin, moxifloxacin, and metronidazole.ResultsThe categorical agreement (CA) between the two methods was >90.0% for imipenem, meropenem, clindamycin, and metronidazole. However, the CA for piperacillintazobactam was low, at 83.2%. Major errors were found: 5.4% for imipenem, 7.4% for meropenem, and 12.8% for piperacillin-tazobactam. All minor errors were <10%. We propose using the area of technical uncertainty (ATU) zone-overlapping area for susceptible and resistant strains to reduce errors in the DDT. Outside the ATU, the CAs of cefoxitin, cefotetan, and piperacillin-tazobactam were >90.0%, whereas that of moxifloxacin was increased to 88.5%.ConclusionsThe DDT can be a useful alternative antimicrobial susceptibility test for BFG isolates when using the ATU zone to reduce errors.

11 Jan 2024·Journal of Medicinal ChemistryQ1 · MEDICINE

Design, Synthesis, and Evaluation of Cephamycin-Based Antisporulation Agents targeting Clostridioides difficile

Q1 · MEDICINE

Article

Author: Webb, Chaille T ; Pyne, Stephen G ; Lyras, Dena ; Revitt-Mills, Sarah A ; Keller, Paul A ; McGowan, Sheena ; Bate, Clara E ; Cun, Wendy Y ; Yu, Haibo ; Srikhanta, Yogitha N ; Hutton, Melanie L

With the aim of discovering small molecule inhibitors of the sporulation process in Clostridioides difficile, we prepared a series of C-7 α-(4-substituted-1H-1,2,3-triazol-1-yl)acetamide analogues of cefotetan, a known inhibitor of the C. difficile sporulation-specific protein target CdSpoVD. These analogues were evaluated using both in vitro binding assays with CdSpoVD and antisporulation assays against C. difficile. Further design concepts were aided utilizing the predicted docking scores (DS) using both AlphaFold (AF) models, and a crystal structure of the CdSpoVD protein (PDB 7RCZ). Despite being 1 order of magnitude more potent as a sporulation inhibitor than cefotetan, in vivo studies on compound 6a in a murine-model of C. difficile infection demonstrated comparable spore shedding capabilities as cefotetan. Importantly, compound 6a had no concerning broad spectrum antibacterial activities, toxicity, or hemolytic activity and thus has potential for further drug development.

100 Deals associated with Cefotetan Disodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02228	Cefotetan Disodium	J01DC05	DB01330

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	US	PAI Holdings LLC	27 Dec 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Genitourinary tract infection	Phase 2	CN	Hubei Jumpcan Pharmaceutical Co., Ltd.	12 Apr 2012
Respiratory Tract Infections	Phase 2	CN	Hubei Jumpcan Pharmaceutical Co., Ltd.	12 Apr 2012
Bacterial Infections	Preclinical	CN	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	10 Oct 2012
Urinary Tract Infections	Preclinical	US	B. Braun Medical, Inc.	09 Aug 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00090272 (0826-039, Pubmed \| Br Dent J)	Phase 3	-	1,002	Ertapenem	tgeihxliyg(uqyhznscnd) = the overall incidence of Clostridium difficile infection was 1.7% in the ertapenem group and 0.6% in the cefotetan group (P=0.22) hcqyvepept (gudqzdbxhn )	-	21 Dec 2006
				Cefotetan